Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:ECOR NASDAQ:SURG NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$11.05+14.4%$10.50$7.19▼$14.76$55.69M0.299,666 shs270 shsECORelectroCore$6.32-1.5%$6.58$4.16▼$8.64$52.22M0.6867,085 shs9,484 shsSURGSurgePays$0.54-2.9%$0.74$0.46▼$3.45$13.54M0.32350,373 shs8,086 shsTELATELA Bio$1.01-0.6%$0.75$0.50▼$2.20$46.11M1.3199,823 shs30,367 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor0.00%-4.69%+5.11%-18.78%+28.39%ECORelectroCore0.00%-3.46%+5.43%+19.81%+34.95%SURGSurgePays0.00%-2.90%-17.18%-44.47%-80.18%TELATELA Bio0.00%+3.12%+79.77%+25.93%-3.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$11.05+14.4%$10.50$7.19▼$14.76$55.69M0.299,666 shs270 shsECORelectroCore$6.32-1.5%$6.58$4.16▼$8.64$52.22M0.6867,085 shs9,484 shsSURGSurgePays$0.54-2.9%$0.74$0.46▼$3.45$13.54M0.32350,373 shs8,086 shsTELATELA Bio$1.01-0.6%$0.75$0.50▼$2.20$46.11M1.3199,823 shs30,367 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor0.00%-4.69%+5.11%-18.78%+28.39%ECORelectroCore0.00%-3.46%+5.43%+19.81%+34.95%SURGSurgePays0.00%-2.90%-17.18%-44.47%-80.18%TELATELA Bio0.00%+3.12%+79.77%+25.93%-3.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 2.50Moderate BuyN/AN/AECORelectroCore 2.00Hold$18.00185.04% UpsideSURGSurgePays 2.00Hold$5.00827.64% UpsideTELATELA Bio 2.40Hold$2.20116.96% UpsideCurrent Analyst Ratings BreakdownLatest SURG, TELA, DXR, and ECOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026TELATELA Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026SURGSurgePays Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.75 ➝ $5.003/27/2026DXRDaxor Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/27/2026ECORelectroCore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ECORelectroCore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/27/2026TELATELA Bio Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$5.00 ➝ $3.003/25/2026TELATELA Bio Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$1.25 ➝ $1.003/25/2026TELATELA Bio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.003/25/2026TELATELA Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $2.002/23/2026SURGSurgePays Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold2/11/2026DXRDaxor Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/AECORelectroCore$34.90M1.50N/AN/A($0.21) per share-30.07SURGSurgePays$56.96M0.24N/AN/A($0.66) per share-0.82TELATELA Bio$80.28M0.57N/AN/A$0.16 per share6.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AN/AECORelectroCore-$13.97M-$1.77N/AN/AN/A-44.08%-1,956.38%-83.30%N/ASURGSurgePays-$36.07M-$1.81N/A8.98N/A-63.32%-967.32%-241.91%5/12/2026 (Estimated)TELATELA Bio-$38.83M-$0.83N/AN/AN/A-48.37%-433.58%-53.00%5/12/2026 (Estimated)Latest SURG, TELA, DXR, and ECOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 2025SURGSurgePays-$0.16N/AN/AN/A$15.50 millionN/A5/12/2026Q1 2026TELATELA Bio-$0.14N/AN/AN/A$18.60 millionN/A5/6/2026Q1 2026ECORelectroCore-$0.59-$0.59N/A-$0.59$9.01 million$9.58 million3/24/2026Q4 2025TELATELA Bio-$0.18-$0.16+$0.02-$0.17$21.04 million$20.87 million3/19/2026Q4 2025ECORelectroCore-$0.35-$0.34+$0.01-$0.34$9.09 million$9.24 million3/2/2026Q2 2025DXRDaxorN/A-$0.1010N/A-$0.1010N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AECORelectroCoreN/A1.020.86SURGSurgePaysN/A0.380.37TELATELA Bio8.824.203.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%ECORelectroCore26.74%SURGSurgePays6.94%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%ECORelectroCore13.80%SURGSurgePays29.10%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor375.04 million2.04 millionNot OptionableECORelectroCore508.30 million7.15 millionNot OptionableSURGSurgePays4025.12 million17.81 millionOptionableTELATELA Bio12044.77 million42.66 millionOptionableSURG, TELA, DXR, and ECOR HeadlinesRecent News About These CompaniesTELA Bio (TELA) to Release Earnings on Tuesday4 hours ago | americanbankingnews.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comTELA Bio (TELA) Projected to Post Earnings on TuesdayMay 5, 2026 | marketbeat.comAxos, Gallagher and TELA Bio post strong growth and strategic movesMay 1, 2026 | msn.comTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports ...April 30, 2026 | markets.businessinsider.comTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesApril 30, 2026 | globenewswire.comTELA Bio, Inc. (NASDAQ:TELA) Given Consensus Recommendation of "Hold" by AnalystsApril 30, 2026 | americanbankingnews.comTELA Bio (TELA) Gets a Buy from Canaccord GenuityApril 26, 2026 | theglobeandmail.comTELA Bio to Announce First Quarter 2026 Financial ResultsApril 21, 2026 | globenewswire.comTELA Bio (TELA) price target decreased by 34.78% to 2.30April 10, 2026 | msn.comTELA Bio, Inc. Q4 2025 Earnings Call SummaryMarch 26, 2026 | finance.yahoo.comTELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 26, 2026 | finanznachrichten.deTELA Bio (TELA) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | finance.yahoo.comTELA Bio Q4 Earnings Call HighlightsMarch 26, 2026 | defenseworld.netDTELA Bio Analysts Cut Their Forecasts After Q4 ResultsMarch 25, 2026 | benzinga.comTELA Bio, Inc. (NASDAQ:TELA) Q4 2025 Earnings Call TranscriptMarch 25, 2026 | insidermonkey.comTELA Bio, Inc. (NASDAQ:TELA) Q4 2025 earnings call transcriptMarch 25, 2026 | msn.comTELA Bio Inc (TELA) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic ...March 25, 2026 | uk.finance.yahoo.comTela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformationMarch 24, 2026 | seekingalpha.comTELA Bio, Inc. (TELA) Q4 2025 Earnings Call TranscriptMarch 24, 2026 | seekingalpha.comTELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue EstimatesMarch 24, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAlphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 20265 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026GPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 2026Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings ResultsBy Thomas Hughes | April 14, 202695% Options Surge: Smart Money Bets Big on a Super Micro Bounce By Jeffrey Neal Johnson | April 15, 2026SURG, TELA, DXR, and ECOR Company DescriptionsDaxor NASDAQ:DXR$11.05 +1.39 (+14.38%) As of 10:16 AM Eastern This is a fair market value price provided by Massive. Learn more.Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.electroCore NASDAQ:ECOR$6.32 -0.10 (-1.48%) As of 10:40 AM Eastern This is a fair market value price provided by Massive. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.SurgePays NASDAQ:SURG$0.54 -0.02 (-2.88%) As of 10:32 AM Eastern This is a fair market value price provided by Massive. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee.TELA Bio NASDAQ:TELA$1.01 -0.01 (-0.59%) As of 10:40 AM Eastern This is a fair market value price provided by Massive. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance The Stars Are Aligning For Apple: Get Ready for $300 3 Under-The-Radar Small Caps Making New All-Time Highs Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
